Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

PPAR-γ receptor ligands: novel therapy for pituitary adenomas
Anthony P. Heaney, … , Manory Fernando, Shlomo Melmed
Anthony P. Heaney, … , Manory Fernando, Shlomo Melmed
Published May 1, 2003
Citation Information: J Clin Invest. 2003;111(9):1381-1388. https://doi.org/10.1172/JCI16575.
View: Text | PDF
Article Aging Article has an altmetric score of 6

PPAR-γ receptor ligands: novel therapy for pituitary adenomas

  • Text
  • PDF
Abstract

Pituitary tumors cause considerable morbidity due to local invasion, hypopituitarism, or hormone hypersecretion. In many cases, no suitable drug therapies are available, and surgical excision is currently the only effective treatment. We show here abundant expression of nuclear hormone receptor PPAR-γ in all of 39 human pituitary tumors. PPAR-γ activating thiazolidinediones (TZDs) rosiglitazone and troglitazone induced G0-G1 cell-cycle arrest and apoptosis in human, rat somatolactotroph, and murine gonadotroph pituitary tumor cells, and suppressed in vitro hormone secretion. In vivo development and growth of murine somatolactotroph and gonadotroph tumors, generated by subcutaneous injection of prolactin-secreting (PRL-secreting) and growth hormone–secreting (GH-secreting) GH3 cells, luteinizing hormone–secreting (LH-secreting) LβT2 cells, and α-T3 cells, was markedly suppressed in rosiglitazone-treated mice, and serum GH, PRL, and LH levels were attenuated in all treated animals (P < 0.009). These results demonstrate that PPAR-γ is an important molecular target in pituitary adenoma cells and PPAR-γ ligands inhibit tumor cell growth and GH, PRL, and LH secretion in vitro and in vivo. TZDs are proposed as novel oral medications for managing pituitary tumors.

Authors

Anthony P. Heaney, Manory Fernando, Shlomo Melmed

×

Total citations by year

Year: 2025 2024 2023 2021 2020 2019 2018 2017 2016 2015 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Total
Citations: 1 1 1 3 6 1 2 2 2 3 2 3 3 4 6 5 1 2 2 3 2 55
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (55)

Title and authors Publication Year
Diabetes mellitus secondary to endocrine diseases: a position statement of the working group of the club of the Italian society of endocrinology (SIE)-Nutrition hormones and metabolism.
Barrea L, Caprio M, Perrini S, Camajani E, Crafa A, Gangitano E, Gorini S, Sciacca L, Verde L, Albertelli M, Ferone D, Giorgino F, Colao A, Aimaretti G, Muscogiuri G
Journal of endocrinological investigation 2025
Longitudinal multiomics analysis of aggressive pituitary neuroendocrine tumors: comparing primary and recurrent tumors from the same patient, reveals genomic stability and heterogeneous transcriptomic profiles with alterations in metabolic pathways
Taniguchi-Ponciano K, Hinojosa-Alvarez S, Hernandez-Perez J, Chavez-Santoscoy RA, Remba-Shapiro I, Guinto G, Magallon-Gayon E, Telles-Ramirez B, de Leon-Conconi RP, Vela-Patiño S, Andonegui-Elguera S, Cano-Zaragoza A, Martinez-Mendoza F, Kerbel J, Loza-Mejia M, Rodrigo-Salazar J, Mendez-Perez A, Aguilar-Flores C, Chavez-Gonzalez A, Ortiz-Reyes E, Gomez-Apo E, Bonifaz LC, Marrero-Rodriguez D, Mercado M
Acta Neuropathologica Communications 2024
Secondary diabetes mellitus in acromegaly.
Moustaki M, Paschou SA, Xekouki P, Kotsa K, Peppa M, Psaltopoulou T, Kalantaridou S, Vryonidou A
Endocrine 2023
Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver
Y Zhang, M Wang, C Ji, Z Chen, H Yang, L Wang, Y Yu, N Qiao, Z Ma, Z Ye, X Shao, W Liu, Y Wang, W Gong, V Melnikov, L Hu, EJ Lee, H Ye, Y Wang, Y Li, M He, Y Zhao, Z Zhang
iScience 2021
Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain
N Kumar, N Sharma, R Khera, R Gupta, S Mehan
Metabolic Brain Disease 2021
Prenatal exposure to the phthalate DEHP impacts reproduction-related gene expression in the pituitary.
Ge X, Weis K, Flaws J, Raetzman L
Reproductive toxicology (Elmsford, N.Y.) 2021
Nuclear Receptors as Regulators of Pituitary Corticotroph Pro-Opiomelanocortin Transcription
D Zhang, AP Heaney
Cells 2020
PPAR-Mediated Toxicology and Applied Pharmacology
, Y Zhang, S Zhu, Y Luo, P Xu, Z Huang
Cells 2020
Integrated multi-omics profiling of nonfunctioning pituitary adenomas
Z Wei, C Zhou, M Li, R Huang, H Deng, S Shen, R Wang
Pituitary 2020
CB13, a novel PPARγ ligand, overcomes radio-resistance via ROS generation and ER stress in human non-small cell lung cancer
TW Kim, DW Hong, SH Hong
Cell Death and Disease 2020
CB11, a novel purine-based PPARɣ ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells
TW Kim, DW Hong, JW Park, SH Hong
British Journal of Cancer 2020
Rosiglitazone affects the progression of surgically‑induced endometriosis in a rat model
S Zhang, L Zhuang, Q Liu, X Yu, Q Min, M Chen, Q Chen
Molecular medicine reports 2020
The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome
M Barbot, F Ceccato, C Scaroni
Frontiers in Endocrinology 2019
Pituitary-Directed Therapies for Cushing’s Disease
F Langlois, J Chu, M Fleseriu
Frontiers in Endocrinology 2018
Peroxisome Proliferator-Activated Receptor gamma negatively regulates liver regeneration after partial hepatectomy via the HGF/c-Met/ERK1/2 pathways
Z Cheng, L Liu, XJ Zhang, M Lu, Y Wang, V Assfalg, M Laschinger, G von Figura, Y Sunami, CW Michalski, J Kleeff, H Friess, D Hartmann, N Hüser
Scientific Reports 2018
Autocrine IL-6 mediates pituitary tumor senescence
M Sapochnik, MR Haedo, M Fuertes, P Ajler, G Carrizo, A Cervio, G Sevlever, GK Stalla, E Arzt
Oncotarget 2017
Bioinformatic analysis of gene expression profiles of pituitary gonadotroph adenomas
Z Hou, J Yang, G Wang, C Wang, H Zhang
Oncology Letters 2017
Peroxisome Proliferator-Activated Receptors in Female Reproduction and Fertility
M Vitti, GD Emidio, MD Carlo, G Carta, A Antonosante, PG Artini, A Cimini, C Tatone, E Benedetti
PPAR Research 2016
Developmental and Functional Effects of Steroid Hormones on the Neuroendocrine Axis and Spinal Cord
L Zubeldia-Brenner, CE Roselli, SE Recabarren, MC Deniselle, HE Lara
Journal of Neuroendocrinology 2016
The Treatment of Cushing's Disease
R Pivonello, MD Leo, A Cozzolino, A Colao
Endocrine reviews 2015
Peroxisome proliferator-activated receptor gamma signaling in human sperm physiology
LL Liu, H Xian, JC Cao, C Zhang, YH Zhang, MM Chen, Y Qian, M Jiang
Asian Journal of Andrology 2015
Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?
S Cetinkalp, IY Simsir, F Sahin, G Saydam, AU Ural, C Yilmaz
Saudi Pharmaceutical Journal 2015
PPARγ E3 ubiquitin ligase regulates MUC1-C oncoprotein stability
Y Hou, J Gao, H Xu, Y Xu, Z Zhang, Q Xu, C Zhang
Oncogene 2013
Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case–control study
SS Chang, HY Hu
BMC Cancer 2013
PPARγ is an E3 ligase that induces the degradation of NFκB/p65
Y Hou, F Moreau, K Chadee
Nature Communications 2012
PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis
L Sabatino, A Fucci, M Pancione, V Colantuoni
PPAR Research 2012
Effect of troglitazone on radiation sensitivity in cervix cancer cells
Z An, X Liu, H Song, C Choi, WD Kim, JR Yu, WY Park
Radiation Oncology Journal 2012
Rosiglitazone as an option for patients with acromegaly: a case series
HE Tamez-Pérez, A Bahena-García, MD de Ossio, H Gutiérrez-Hermosillo, AL Tamez-Peña
Journal of medical case reports 2011
Thiazolidinediones on PPARγ: The Roles in Bone Remodeling
W Wei, Y Wan
PPAR Research 2011
Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line
R Miao, T Xu, L Liu, M Wang, Y Jiang, J Li, R Guo
Experimental and therapeutic medicine 2011
PPARG Regulates Gonadotropin-Releasing Hormone Signaling in LbetaT2 Cells In Vitro and Pituitary Gonadotroph Function In Vivo in Mice1
S Sharma, PM Sharma, DS Mistry, RJ Chang, JM Olefsky, PL Mellon, NJ Webster
Biology of reproduction 2010
Effectofrosiglitazoneonserum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: Results froma pilot phase 2 study
F Bogazzi, G Rossi, M Lombardi, F Raggi, C Urbani, C Sardella, C Cosci, E Martino
Journal of Endocrinological Investigation 2010
A case of fugitive acromegaly, initially presented as invasive prolactinoma
JS Lim, CR Ku, MK Lee, TS Kim, SH Kim, EJ Lee
Endocrine 2010
Minireview: Nuclear Receptor-Controlled Steroid Hormone Synthesis and Metabolism
J He, Q Cheng, W Xie
Molecular Endocrinology 2010
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009
Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells
CW Cheon, DH Kim, DH Kim, YH Cho, JH Kim
World journal of gastroenterology : WJG 2009
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor
MS Thearle, PU Freda, JN Bruce, SR Isaacson, Y Lee, RL Fine
Pituitary 2009
The Multiple Endocrine Neoplasia Type 1 (MEN1) Tumor Suppressor Regulates Peroxisome Proliferator-Activated Receptor γ-Dependent Adipocyte Differentiation
KM Dreijerink, RA Varier, O van Beekum, EH Jeninga, JW Höppener, CJ Lips, JA Kummer, E Kalkhoven, HT Timmers
Molecular and cellular biology 2009
Medical treatment of Cushing's disease: Overview and recent findings.
Praw SS, Heaney AP
International journal of general medicine 2009
Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis.
Kocdor H, Kocdor MA, Canda T, Gurel D, Cehreli R, Yilmaz O, Alakavuklar M, Guner G
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2009
Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement
BM Biller, AB Grossman, PM Stewart, S Melmed, X Bertagna, J Bertherat, M Buchfelder, A Colao, AR Hermus, LJ Hofland, A Klibanski, A Lacroix, JR Lindsay, J Newell-Price, LK Nieman, S Petersenn, N Sonino, GK Stalla, B Swearingen, ML Vance, JA Wass, M Boscaro
The Journal of clinical endocrinology and metabolism 2008
Peroxisome proliferator-activated receptors and progression of colorectal cancer
D Wang, RN Dubois
PPAR Research 2008
A Novel Mechanism of PPARgamma Regulation of TGFbeta1: Implication in Cancer Biology
CH Lee, HD Kim, SM Shin, SG Kim
PPAR Research 2008
PPAR Ligands for Cancer Chemoprevention
Y Yasui, M Kim, T Tanaka
PPAR Research 2008
PPARs and Female Reproduction: Evidence from Genetically Manipulated Mice
J Yang, L Chen, X Zhang, Y Zhou, D Zhang, M Huo, Y Guan
PPAR Research 2008
PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study
DI Lebovic, JM Mwenda, DC Chai, MD Mueller, A Santi, S Fisseha, T D'Hooghe
Fertility and Sterility 2007
The Murine p8 Gene Promoter Is Activated by Activating Transcription Factor 4 (ATF4) in the Gonadotrope-Derived LβT2 Cell Line
CM Passe, G Cooper, CC Quirk
Endocrine 2006
The Emerging Role of Pituitary Tumor Transforming Gene in Tumorigenesis
Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N
Clinical medicine & research 2006
Update on the medical management of pituitary adenomas
CA Pickett
Current Neurology and Neuroscience Reports 2005
Peroxisome proliferator-activated receptor (PPAR)gamma is highly expressed in normal human pituitary gland.
Bogazzi F, Russo D, Locci MT, Chifenti B, Ultimieri F, Raggi F, Viacava P, Cecchetti D, Cosci C, Sardella C, Acerbi G, Gasperi M, Martino E
Journal of Endocrinological Investigation 2005
Crosstalk of oncogenic and prostanoid signaling pathways
R Mller
Journal of Cancer Research and Clinical Oncology 2004
Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity
S Giannini, M Serio, A Galli
Journal of Endocrinological Investigation 2004
PPAR-γ in Cushing's Disease
AP Heaney
Pituitary 2004
Mechanisms for pituitary tumorigenesis: the plastic pituitary
S Melmed
Journal of Clinical Investigation 2003
Novel Pituitary Ligands: Peroxisome Proliferator Activating Receptor-γ
AP Heaney
Pituitary 2003

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
24 readers on Mendeley
See more details